Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| We were also pleased with the positive top line data we reported last month from the Phase 2 OASIS HAE study of donidalorsen for the prophylactic treatment of hereditary angioedema |
| Additionally, we’re pleased that the FDA has granted olezarsen both orphan drug designation and breakthrough therapy designation, which can help expedite the review of this new medicine for the treatment of FCS |
| We are very proud of the remarkable progress we made last year, and we’re very much looking forward to building on this positive momentum this year |
| We have great momentum and a substantial number of upcoming value-driving catalysts |
| It’s really shaping up to be a really remarkable exciting 2024 |
| We expect to carry the positive momentum generated by our strong 2023 performance into this year by deploying our capital resources towards growth opportunities to unlock next level value |
| We really are excited about the great progress we have already made this year and everything ahead of us |
| And we expect that, that will be positive and based on the numbers and on the duration that we put into this 2 years ago, we’re very confident in the readout of this study |
| In the Phase 3 study, donidalorsen met the primary endpoint with a statistically significant reduction in the rate of HAE attacks in patients treated every 4 weeks or every 8 weeks, along with a favorable safety and tolerability profile |
| By significantly, we significantly exceeded 2023 revenue guidance by more than $200 million, earning revenues of $325 million and $788 million for the fourth quarter and full year, respectively |
| As a reminder, in the BALANCE study, the 80-milligram dose of olezarsen demonstrated statistically significant reductions in triglycerides, robust target engagement and a favorable safety and tolerability profile |
| And we are also pleased to cap off a highly successful year with the approval of WAYNUA for ATTR polyneuropathy in late December |
| 2023 was a strong year underscored by similarly strong financial results, in which we delivered substantial revenue, while simultaneously advancing our pipeline and preparing to bring WAINUA, olezarsen and donidalorsen to market |
| The Angelman study is one of several mid-stage data readouts we have planned for 2024 that if positive, could further add to our rich Phase 3 pipeline and bolster our ability to deliver a steady cadence of transformative medicines to patients for years to come |
| Based on its strong overall profile, including highly positive Phase 3 data, which we reported last year, together with the freedom of simple at-home monthly self-administration, we believe WAINUA is very well positioned to become the therapy of choice for ATTR patients who remain underserved by current therapies |
| And I am very pleased to actually see how the joint teams are executing to plan |
| Receiving this designation further reinforces our confidence in WAINUA’s potential to be a transformational treatment in this underserved and growing patient population |
| And with AstraZeneca’s global leadership in the commercialization of novel cardiovascular treatments, coupled with our leadership in TTR amyloidosis, we believe we are very well positioned to bring WAINUA to patients in the U.S |
| We also recently delivered positive Phase 3 top line data readouts for two additional important medicines: olezarsen in FCS and donidalorsen in HAE |
| In the Phase 3 BALANCE study in patients with FCS, olezarsen showed significant triglyceride reductions, substantial reductions in acute pancreatitis events and a favorable safety and tolerability profile |
| And we do believe that the donidalorsen data will actually provide that with our positive top line results from the OASIS study hitting on a multitude of different efficacy parameters, safety, tolerability and self-administered dual volume injection either every four weeks or eight weeks, we can actually really change the treatment paradigm here |
| We reported multiple positive key readouts over the past year and are positioned to deliver additional important results in the near-term |
| Additionally, Otsuka is preparing to submit for marketing approval in Europe, and we’re pleased that we just recently received orphan drug designation for donidalorsen in the EU |
| At Ionis, we are proud of our scientific heritage |
| Yes, we are very well positioned with the product profile as well as the self-administration profile that you just mentioned |
| Based on our Phase 3 results and a durable efficacy and favorable safety data seen long term in the ongoing Phase 2 open-label extension study, we believe donidalorsen could be an attractive new treatment option for patients with HAE |
| And what I mean by that, based on the Phase 3 results, donidalorsen has the potential to extend dosing intervals to monthly or every 2 months using an auto-injector from the current standard of care, which is dosed every 2 to 4 weeks using a vial and a syringe, and with an attractive efficacy, safety and tolerability profile demonstrated in the OASIS-HAE Phase 3 study, we expect donidalorsen to be a treatment of choice for many HAE patients |
| We also continued to make great strides last year in advancing our industry-leading RNA-targeting technology |
| We also made substantial progress in our efforts to deliver our CNS medicines across the blood-brain barrier |
| This adds to our multipronged approach to traverse the blood-brain barrier with our novel treatments to further strengthen our leadership position in treating CNS diseases |
| Statement |
|---|
| We project meaningful R&D revenue from our partnered programs this year, although we anticipate R&D revenue will be lower than it was last year |
| With meaningful revenues and modest expense growth, we are projecting a non-GAAP operating loss of less than $475 million |
| We have to remind ourselves that cardiomyopathy patients, this is a serious disease, and it’s a terminal illness |
| So, we actually slowed down, stopped enrollment at one point, a couple of years ago in the U.S., except for sites that had the hereditary patients that they were able to continue to bring in because we got a good percentage of those patients in the study, too |
| They would be at risk through attacks if they were being washed out |
| So, I am not sure we have really good answer |
Please consider a small donation if you think this website provides you with relevant information